A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY WITH OPEN-LABEL EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN STUDY PARTICIPANTS WITH PALMOPLANTAR PUSTULOSIS

Registry ID

PPP001

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

UCB INC

Start date

2026-01-14

Last update

2025-10-21

Conditions

• PALMOPLANTAR PUSTULOSIS

Related clinical trials

• A PROOF-OF-CONCEPT PHASE 2A, DOUBLE-BLIND, 2-ARM TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF TWICE DAILY DELGOCITINIB CREAM 20 MG/G COMPARED WITH CREAM VEHICLE DURING A 16-WEEK TREATMENT PERIOD IN ADULT SUBJECTS WITH MILD TO SEVERE PALMOPLANTAR PUSTULOSIS
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIST4721 IN SUBJECTS WITH PALMOPLANTAR PUSTULOSIS
• MULTI-CENTER, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, PHASE IIB DOSE-FINDING STUDY TO EVALUATE EFFICACY AND SAFETY OF DIFFERENT SUBCUTANEOUS DOSES OF BI 655130 IN PATIENTS WITH MODERATE TO SEVERE PALMOPLANTAR PUSTULOSIS (PPP)

View on source registry